Hidden gut issue in Crohn's patients under the microscope

NCT ID NCT03915262

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how common exocrine pancreatic insufficiency (EPI) is in people with active Crohn's disease who are starting a biologic therapy. EPI means the pancreas doesn't make enough enzymes to digest food properly. Researchers will check for EPI at the start of treatment and again 14 weeks later. The goal is to better understand this condition in Crohn's patients and how it changes with treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Service d'Hépato-Gastroentérologie, Centre Hospitalier Lyon-Sud, HCL

    RECRUITING

    Pierre-Bénite, 69495, France

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact